Gastrointestinal Cancer | Specialty

Frontline Treatment Selection in RAS Wild-Type mCRC

July 13th 2015

TAS-102 in Metastatic Colorectal Cancer

July 13th 2015

SIRFLOX Study in Metastatic Colorectal Cancer

July 13th 2015

Regorafenib in Metastatic Colorectal Cancer

July 13th 2015

Mismatch Repair Deficiency in Colorectal Cancer

July 13th 2015

Adjuvant Aspirin in Colorectal Cancer

July 13th 2015

Advances in Hepatitis C Care Improve Outlook in HCC

July 10th 2015

Michael P. Manns, MD, discusses the relationship between advances in hepatitis C care and the future of HCC treatment.

Dr. Argilés on BRAF-Mutations in Colorectal Cancer

July 10th 2015

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

2015 World Congress on GI Cancer

July 9th 2015

Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients

July 8th 2015

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

New Molecular Testing Guidelines Pending for Colorectal Cancer

July 8th 2015

All patients with colorectal cancer being considered for treatment with the EGFR inhibitors cetuximab and panitumumab should undergo extended RAS mutational testing to predict their response to the drugs.

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

July 7th 2015

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

July 4th 2015

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

July 4th 2015

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

July 4th 2015

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Regorafenib Benefits Consistent in "Real World" mCRC Population

July 3rd 2015

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

July 3rd 2015

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC

July 3rd 2015

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

Dr. Andrew Zhu on Ramucirumab for HCC

July 3rd 2015

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.